COGZF Stock Chart & Stats
$2.40
-$0.24(-12.06%)
At close: 4:00 PM EDT
$2.40
-$0.24(-12.06%)
Day’s Range― - ―
52-Week Range$1.00 - $2.40
Previous CloseN/A
Volume3.00K
Average Volume (3M)1.10K
Market Cap
$374.22M
Enterprise Value$434.77
Total Cash (Recent Filing)$34.77M
Total Debt (Recent Filing)$359.02K
Price to Earnings (P/E)32.9
Beta0.36
Next Earnings
Feb 24, 2027EPS Estimate
0.04Next Dividend Ex-DateN/A
Dividend Yield1.74%
Share Statistics
EPS (TTM)0.07
Shares Outstanding169,919,360
10 Day Avg. Volume1,514
30 Day Avg. Volume1,097
Financial Highlights & Ratios
PEG Ratio0.50
Price to Book (P/B)8.01
Price to Sales (P/S)7.79
P/FCF Ratio50.90
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$2.46Price Target Upside2.51% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.06
Revenue Forecast (FY)$51.95M
Bulls Say, Bears Say
Bulls Say
Contracted Revenue VisibilityThe larger contracted revenue base provides stronger forward visibility than relying solely on new bookings. It supports FY'27 planning, reduces demand uncertainty and gives management a foundation for sustaining growth over the next several reporting periods.
Conservative Balance SheetMinimal leverage limits financial risk and preserves flexibility to fund product development, pursue growth initiatives and manage periods of uneven cash conversion. The expanding equity base and attractive returns on equity further support long-term financial resilience.
Scalable Growth And DiversificationRising trial volume increases the platform's operating scale, while growth in mood, sleep and other neurological disorders reduces dependence on Alzheimer's studies. This broader clinical footprint can support recurring demand across more therapeutic areas.
Bears Say
Uneven Cash ConversionCash generation has not been as consistent as reported earnings, indicating working-capital or timing effects. Persistent divergence could limit internally funded investment and make results less predictable even while accounting profitability remains solid.
Margin Pressure From InvestmentPlanned capability and AI investment may delay further margin expansion and create execution demands before efficiency benefits emerge. The year-on-year gross-margin decline also shows that scaling revenue does not automatically ensure stable profitability.
Revenue Timing And Channel Execution RiskContract conversion timing can make reported growth uneven, complicating forecasting and resource planning. Growing reliance on still-maturing partners adds execution and concentration risk until channel processes and contribution become more established.
Cogstate Ltd News
COGZF FAQ
What was Cogstate Ltd’s price range in the past 12 months?
Cogstate Ltd lowest stock price was $1.00 and its highest was $2.40 in the past 12 months.
What is Cogstate Ltd’s market cap?
Cogstate Ltd’s market cap is $374.22M.
When is Cogstate Ltd’s upcoming earnings report date?
Cogstate Ltd’s upcoming earnings report date is Feb 24, 2027 which is in 179 days.
How were Cogstate Ltd’s earnings last quarter?
Cogstate Ltd released its earnings results on Aug 17, 2026. The company reported $0.042 earnings per share for the quarter, beating the consensus estimate of $0.038 by $0.004.
Is Cogstate Ltd overvalued?
According to Wall Street analysts Cogstate Ltd’s price is currently Undervalued.
Does Cogstate Ltd pay dividends?
Cogstate Ltd pays a Notavailable dividend of $0.029 which represents an annual dividend yield of 1.74%. See more information on Cogstate Ltd dividends here
What is Cogstate Ltd’s EPS estimate?
Cogstate Ltd’s EPS estimate is 0.04.
How many shares outstanding does Cogstate Ltd have?
Cogstate Ltd has 169,919,360 shares outstanding.
What happened to Cogstate Ltd’s price movement after its last earnings report?
Cogstate Ltd reported an EPS of $0.042 in its last earnings report, beating expectations of $0.038. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Cogstate Ltd?
Currently, no hedge funds are holding shares in COGZF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cogstate Ltd Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$2.46 (2.51% Upside)
$2.46 (2.51% Upside)
Blogger Sentiment
Bullish
COGZF Sentiment 100%
Sector Average 61%
Sector Average 61%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
140.24%
12-Months-Change
Fundamentals
Return on Equity
1.74%
Trailing 12-Months
Asset Growth
20.52%
Trailing 12-Months
Company Description
Cogstate Ltd
Melbourne, Australia-based Cogstate Limited, established in 1999, is a neuroscience technology company specializing in computerized cognitive assessments and digital solutions for clinical outcome evaluations. Its comprehensive suite of cognitive services includes project and data management, scientific consulting, statistical analysis, procurement of assessment scales, rater training, and monitoring solutions. The company operates through two distinct divisions. The Clinical Trials segment delivers technology and support services designed to measure the impact of diseases, pharmaceuticals, medical devices, or other interventions on human participants in clinical studies, primarily serving pharmaceutical and biotechnology clients. Concurrently, its Healthcare segment offers Cognigram, a system facilitating regular and standardized testing to assist primary care physicians and hospitals in the early identification of cognitive decline. By June 30, 2022, Cogstate had participated in an estimated 1,800 academic research initiatives.
COGZF Company Deck
COGZF Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call communicated strong, diversified top-line growth, record sales and a materially expanded contracted revenue base, backed by improving second-half margins and completed AI products—positioning the business for continued growth. Management acknowledged near-term margin pressure from purposeful capability investments, conversion timing risk for contracted revenue, a small FX tailwind that may not recur, and dependence on nascent channel partnerships. On balance, the positive operational momentum, robust pipeline and clear technology roadmap outweigh the manageable short-term risks.View all COGZF earnings summariesCOGZF Stock 12 Month Forecast
Average Price Target
$2.46
▲(2.51% Upside)
Technical Analysis
Tali Digital
―
Opyl Ltd.
―
Beamtree Holdings Ltd
―
Alcidion Group Limited
―
PainChek Ltd
―
Ownership Overview
3.83% Insiders
0.48% Mutual Funds
<0.01% Other Institutional Investors
95.68% Public Companies and
Individual Investors